Skip Navigation

JNCI Journal of the National Cancer Institute 2002 94(4):250-251; doi:10.1093/jnci/94.4.250
© 2002 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Marwick, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marwick, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 94, No. 4, 250-251, February 20, 2002
© 2002 Oxford University Press

NEWS

Insurers, Employers Ask for Better Evaluation of New Technologies

Charles Marwick

A group of health insurers and employers have told an Institute of Medicine panel that there needs to be some means to regularly evaluate whether new drugs, devices, or procedures work and whether they are worth the cost. Without such evaluation, insurers cannot decide whether to underwrite new developments as they emerge from clinical research, and employers cannot know whether the insurance coverage that they provide to their employees is benefiting them.

"We are spending billions of dollars and a lot of patient and caregiver time in the development of new and promising technologies, but we have no matching investment in . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
E. J. Sherman, D. M. Rubin, E. Venkatraman, G. K. Schwartz, V. A. Miller, M. H. Radzyner, H. S. Ruchlin, D. Spriggs, and D. G. Pfister
Using Patients As Their Own Controls for Cost Evaluation of Phase I Clinical Trials
J. Clin. Oncol., April 1, 2004; 22(7): 1308 - 1314.
[Abstract] [Full Text] [PDF]